Advances in Cancer Biomarkers : From biochemistry to clinic for a critical revision
Advances in Cancer Biomarkers : From biochemistry to clinic for a critical revision
edited by Roberto Scatena.
- 1st ed. 2015.
- Dordrecht, Netherlands Springer 2015
- 1 recurso en línea (IX, 372 páginas) 27 ilustraciones, 21 ilustraciones en color
- Advances in Experimental Medicine and Biology 867 0065-2598 .
Prelims -- IÂnerality.-Â Tumor markers-a critical revision -- Enzymes.-Ârmones -- Oncofetal proteins.-Âtokeratins -- Carbohydrate markers -- Blood group antigens.-Ânetic markers -- Various protein markers -- IIIÂspectives.-Â role of Circulating tumor Cells as tumor markers -- Index.
At present there are a growing number of biomolecules under investigation to understand their potential role as cancer biomarker for diagnostic, prognostic and therapeutic purposes.Âtriguingly, the state of art on cancer biomarkers research shows interesting and promising results together to clamorous failures. Also from a clinical point of view, there are contradictory results on routine clinical use of the present cancer biomarkers. Some patients may be simplyÂnitored in their course by a periodic blood sample, but sometimes this monitoring shows dramatic limits. A lot of patients show serious and extensive relapses without significant change in serum concentrations of biomarkers tested. Often the physician who should utilize these biomarker does not entirelyÂow their limits and the total potential applications as well and sometimes this knowledge is influenced by economical and marketing strategies. This limited and “pollutedâ€owledge may have dramatic consequences for patient.The aim of this book is to diffuse all aspects of cancer biomarkers, from their biochemical peculiarities to all clinical implications by passing through their physiology and pathophysiology. This critical approach towards old and new cancer biomarkers should foster a deepened and useful understanding of the diagnostic and prognostic index of these fundamental parameters of laboratory medicine and in the same time facilitating the research of new and more sensitive-specific signals of the cancer cell proliferation.
9789401772150
10.1007/978-94-017-7215-0 doi
Farmacología
Farmacología
RC267 / .A383 2015
Prelims -- IÂnerality.-Â Tumor markers-a critical revision -- Enzymes.-Ârmones -- Oncofetal proteins.-Âtokeratins -- Carbohydrate markers -- Blood group antigens.-Ânetic markers -- Various protein markers -- IIIÂspectives.-Â role of Circulating tumor Cells as tumor markers -- Index.
At present there are a growing number of biomolecules under investigation to understand their potential role as cancer biomarker for diagnostic, prognostic and therapeutic purposes.Âtriguingly, the state of art on cancer biomarkers research shows interesting and promising results together to clamorous failures. Also from a clinical point of view, there are contradictory results on routine clinical use of the present cancer biomarkers. Some patients may be simplyÂnitored in their course by a periodic blood sample, but sometimes this monitoring shows dramatic limits. A lot of patients show serious and extensive relapses without significant change in serum concentrations of biomarkers tested. Often the physician who should utilize these biomarker does not entirelyÂow their limits and the total potential applications as well and sometimes this knowledge is influenced by economical and marketing strategies. This limited and “pollutedâ€owledge may have dramatic consequences for patient.The aim of this book is to diffuse all aspects of cancer biomarkers, from their biochemical peculiarities to all clinical implications by passing through their physiology and pathophysiology. This critical approach towards old and new cancer biomarkers should foster a deepened and useful understanding of the diagnostic and prognostic index of these fundamental parameters of laboratory medicine and in the same time facilitating the research of new and more sensitive-specific signals of the cancer cell proliferation.
9789401772150
10.1007/978-94-017-7215-0 doi
Farmacología
Farmacología
RC267 / .A383 2015